PE20020340A1 - Composicion farmaceutica que comprende ester etilico de acido [2r,4s]-4-[(3,5-bis-trifluorometilbencil)metoxicarbonilamino]-2-etil-6-trifluorometil-3,4-dihidro-2h-quinolina-1-carboxilico y atorvastatina o sus metabolitos hidroxilicos - Google Patents

Composicion farmaceutica que comprende ester etilico de acido [2r,4s]-4-[(3,5-bis-trifluorometilbencil)metoxicarbonilamino]-2-etil-6-trifluorometil-3,4-dihidro-2h-quinolina-1-carboxilico y atorvastatina o sus metabolitos hidroxilicos

Info

Publication number
PE20020340A1
PE20020340A1 PE2001000810A PE2001000810A PE20020340A1 PE 20020340 A1 PE20020340 A1 PE 20020340A1 PE 2001000810 A PE2001000810 A PE 2001000810A PE 2001000810 A PE2001000810 A PE 2001000810A PE 20020340 A1 PE20020340 A1 PE 20020340A1
Authority
PE
Peru
Prior art keywords
ethyl
trifluoromethylbenzyl
atorvastatin
quinoline
dihydro
Prior art date
Application number
PE2001000810A
Other languages
English (en)
Inventor
Charles Lester Shear
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20020340A1 publication Critical patent/PE20020340A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a) ESTER ETILICO DE ACIDO [2R,4S]-4-[(3,5-BIS-TRIFLUOROMETILBENCIL)METOXICARBONILAMINO]-2-ETIL-6-TRIFLUOROMETIL-3,4-DIHIDRO-2H-QUINOLINA-1-CARBOXILICO; b) ATORVASTATINA O UN COMPUESTO DE FORMULA I O IA DONDE R1 ES H, OH, O UNA DE SUS SALES Y c) VEHICULO FARMACEUTICAMENTE ACEPTABLE. LA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE ATEROSCLEROSIS, ANGINA DE PECHO, NIVELES ELEVADOS DE COLESTEROL, RIESGO CARDIACO
PE2001000810A 2000-08-15 2001-08-14 Composicion farmaceutica que comprende ester etilico de acido [2r,4s]-4-[(3,5-bis-trifluorometilbencil)metoxicarbonilamino]-2-etil-6-trifluorometil-3,4-dihidro-2h-quinolina-1-carboxilico y atorvastatina o sus metabolitos hidroxilicos PE20020340A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22523800P 2000-08-15 2000-08-15

Publications (1)

Publication Number Publication Date
PE20020340A1 true PE20020340A1 (es) 2002-05-10

Family

ID=22844100

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000810A PE20020340A1 (es) 2000-08-15 2001-08-14 Composicion farmaceutica que comprende ester etilico de acido [2r,4s]-4-[(3,5-bis-trifluorometilbencil)metoxicarbonilamino]-2-etil-6-trifluorometil-3,4-dihidro-2h-quinolina-1-carboxilico y atorvastatina o sus metabolitos hidroxilicos

Country Status (27)

Country Link
US (1) US20020035125A1 (es)
EP (1) EP1309329A2 (es)
JP (1) JP2004506008A (es)
KR (1) KR20030069983A (es)
CN (1) CN1735416A (es)
AP (1) AP2003002743A0 (es)
AU (1) AU2001270937A1 (es)
BG (1) BG107515A (es)
BR (1) BR0113200A (es)
CA (1) CA2419406A1 (es)
CZ (1) CZ2003390A3 (es)
DZ (1) DZ3409A1 (es)
EA (1) EA200300155A1 (es)
EC (1) ECSP034478A (es)
HR (1) HRP20030104A2 (es)
HU (1) HUP0303083A3 (es)
IL (1) IL154348A0 (es)
IS (1) IS6700A (es)
MX (1) MXPA03001419A (es)
NO (1) NO20030725D0 (es)
PA (1) PA8525301A1 (es)
PE (1) PE20020340A1 (es)
SK (1) SK1742003A3 (es)
SV (1) SV2003000600A (es)
TN (1) TNSN01125A1 (es)
UY (1) UY26883A1 (es)
WO (1) WO2002013797A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044459A1 (en) * 2001-09-04 2003-03-06 Pfizer Inc. Biomodulated multiparticulate formulations
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
WO2004056358A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1581210B1 (en) 2002-12-20 2008-03-19 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CA2753318A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
MXPA06001506A (es) * 2003-08-04 2006-05-15 Pfizer Prod Inc Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa.
CA2554982A1 (en) 2003-09-26 2005-04-07 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
AU2005233160B2 (en) * 2004-04-13 2011-06-02 Merck Sharp & Dohme Corp. CETP inhibitors
EP1845953A1 (en) * 2005-02-03 2007-10-24 Pfizer Products Incorporated Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP3578177A1 (en) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
PT2395991E (pt) 2009-02-10 2013-09-03 Amarin Pharmaceuticals Ie Ltd Utilização de éster etílico de ácido eicosapentaenóico para tratamento de hipertrigliceridemia
NZ627238A (en) 2009-04-29 2016-02-26 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition comprising ethyl eicosapentaenoate
NZ789295A (en) 2009-04-29 2024-02-23 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN114053258A (zh) * 2009-06-15 2022-02-18 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
JP2015522029A (ja) 2012-06-29 2015-08-03 アマリン ファーマシューティカルス アイルランド リミテッド スタチン療法中の患者における心血管系イベントの危険性を減少させる方法
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
CN112218630A (zh) 2018-09-24 2021-01-12 阿马里纳药物爱尔兰有限公司 降低受试者的心血管事件的风险的方法
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6462091B1 (en) * 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method

Also Published As

Publication number Publication date
NO20030725D0 (no) 2003-02-14
BG107515A (en) 2003-09-30
KR20030069983A (ko) 2003-08-27
IL154348A0 (en) 2003-09-17
PA8525301A1 (es) 2002-04-25
WO2002013797A2 (en) 2002-02-21
SK1742003A3 (en) 2004-06-08
DZ3409A1 (fr) 2002-02-21
HUP0303083A3 (en) 2005-05-30
CN1735416A (zh) 2006-02-15
AU2001270937A1 (en) 2002-02-25
CA2419406A1 (en) 2002-02-21
HRP20030104A2 (en) 2003-04-30
US20020035125A1 (en) 2002-03-21
HUP0303083A2 (hu) 2003-12-29
EA200300155A1 (ru) 2003-08-28
TNSN01125A1 (fr) 2005-11-10
EP1309329A2 (en) 2003-05-14
JP2004506008A (ja) 2004-02-26
MXPA03001419A (es) 2003-06-06
AP2003002743A0 (en) 2003-03-31
SV2003000600A (es) 2003-01-13
ECSP034478A (es) 2003-03-31
CZ2003390A3 (en) 2004-03-17
WO2002013797A3 (en) 2003-03-13
UY26883A1 (es) 2002-03-22
IS6700A (is) 2003-01-27
BR0113200A (pt) 2003-09-16

Similar Documents

Publication Publication Date Title
PE20020340A1 (es) Composicion farmaceutica que comprende ester etilico de acido [2r,4s]-4-[(3,5-bis-trifluorometilbencil)metoxicarbonilamino]-2-etil-6-trifluorometil-3,4-dihidro-2h-quinolina-1-carboxilico y atorvastatina o sus metabolitos hidroxilicos
PE20030128A1 (es) Formulaciones autoemulsionantes de inhibidores de la proteina de transferencia de colesteril ester
ATE297203T1 (de) Antithrombotische mitteln
AR036331A1 (es) Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores
IS4695A (is) (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem sýklóoxýgenasa-2 tálmar
PE20071150A1 (es) Un proceso para preparar derivados de tetrahidroquinolina
CA2213036A1 (en) Stabilization of an unstable retinoid in oil-in-water emulsions for skin care compositions
KR930016393A (ko) 비아릴 치환된 4-아미노-부티르산 아미드, 이의 제조방법 및 이를 함유하는 약제학적 조성물
ES2138626T3 (es) Acidos (3r,4r)-delta6-tetrahidrocannabinol-7-oicos.
MX9207152A (es) Composiciones farmaceuticas estabilizadas que comprenden un compuesto inhibidor de la hmg-coa reductasa y metodo para su preparacion.
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
AR079399A2 (es) Procedimientos para preparar bifenazato
BR0307801A (pt) Processo para a fabricação de derivados de ácido mevalÈnico inibidores da hmg-coa reductase
BR0109048A (pt) Processo para a sìntese de citalopram
BR9710911A (pt) Um processo para a formação de um perácido e uma composição compreendendo o perácido referido.
BR0210266A (pt) Composição farmacêutica que compreende um inibidor de lìpases, processo para preparar essa composição, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
DK0577040T3 (da) Fremgangsmåde til fremstilling af (3R,5S)6-hydroxy-3,,5-O-isopropyliden-3,5-dihydroxyhexansyre-tert.-butylester
KR970074763A (ko) 불소화된 비타민 d₃ 유사체
ES2176262T3 (es) Acido 2-arilalquil-o arilalquenil-ciclopentano heptenoico, y derivados como agentes terapeuticos.
TW200501995A (en) Treatment for skin
DE69923332D1 (de) Rückfettende ester auf basis von capryl-alkohol und isostearinsäure
ATE45738T1 (de) 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4-(2-oxo-1,3 dioxol-4-yl-methyl)-1-piperazinyl>-3chinolincarbons|uren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel.
ATE295165T1 (de) Mittel zur adjuvanten therapie von demenzen enthaltend alpha-liponsäure
AR008993A1 (es) Sales de esteres etilicos de acidos 3-(2-(4-(4-(amino-imino-metil)-fenil)-4 -metil-2,5-dioxo-imidazolidin-1-il)-acetilamino)-3-fenil-propionicos
FR2395272A1 (fr) Nouveaux medicaments derives de l'acide amidinopenicillanique

Legal Events

Date Code Title Description
FD Application declared void or lapsed